Biomedical Opportunities Leverage VDI Laboratory's validated canine and feline biomarkers for cardiac health, lymphoma, hemangiosarcoma, and sepsis to target veterinary clinics, specialty hospitals, and pet diagnostics distributors seeking expanded diagnostic panels.

Clinical Lab Synergy Promote cross-sell opportunities between the CLIA-certified Glycominds lab and VDI's biomarker portfolio to practices requiring on-site and centralized testing for Multiple Sclerosis and companion animal biomarkers.

Growth Readiness With revenue under one million and a small team, pursue low-friction partnerships, licensing deals, and white-label opportunities with larger veterinary distributors to accelerate market adoption of CardioPet and new biomarkers.

Technology Enablement Highlight VDI’s digital footprint and e-commerce readiness (Shopify, WooCommerce, WordPress, AdRoll) to enable co-marketing campaigns, direct-to-practice sales, and streamlined ordering for new biomarkers.

Strategic Outreach Target veterinary specialty groups, academic institutions, and diagnostic networks focusing on cardiac and oncologic markers to position VDI as an innovative partner for expanded diagnostic capabilities and biomarker research collaborations.